We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Some Inclusion Bodies Protect Cells from Damage by Toxic Misfolded Proteins

By LabMedica International staff writers
Posted on 20 Dec 2012
Researchers studying neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease reported in a recent paper that inclusion bodies, i.e., sites of accumulation of toxic misfolded proteins, which have traditionally been thought to accompany onset of this type of disease, actually have a cell-biological function that is not necessarily related to the disease conditions.

Investigators at the Hebrew University of Jerusalem (Israel) have been studying for several years the JUNQ (juxtanuclear quality control compartment), a novel organellar structure, which serves as a cellular processing center for misfolded and aggregated proteins. More...
JUNQ was shown to be important in managing cellular protein folding quality control, the cellular response to protein aggregation, the formation of prions, and in protecting cells from the toxic effect of aggregation.

In the current paper, which was published in the September 25, 2012, issue of the journal Proceedings of the National Academy of Sciences of the United States of America, the investigators elaborated on the function of JUNQ by presenting direct evidence of a quality control function for JUNQ inclusions in human cultured cells. JUNQ compartments concentrated soluble misfolded proteins together with chaperones and proteasomes, and facilitated their degradation.

The data further showed that the accumulation of insoluble aggregates in the JUNQ inhibited the degradation of other misfolded proteins by sequestering the essential chaperone Hsp70 (heat shock protein 70) and thereby blocking the path of quality control substrates to the proteasome. Rerouting toxic aggregates from the JUNQ to an insoluble polyQ inclusion restored the JUNQ protein degradation function and rescued cell viability.

The authors concluded that toxic and nontoxic inclusions represented different sites of aggregate deposition, with different cell biological properties. They proposed a new approach to treating neurodegenerative diseases that would enhance cellular ability to actively enclose harmful aggregates within protective inclusions, thereby neutralizing the toxic proteins.

Related Links:
Hebrew University of Jerusalem



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Pipette Calibration System
Artel PCS®
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.